Cathy Eng, David H. Johnson Professor of Surgical and Medical Oncology, was named associate director of strategic relations and research partnerships for Vanderbilt-Ingram Cancer Center.
Oxaliplatin-based chemotherapy significantly improves survival only in stage 3 colorectal cancer patients aged 70 or younger, according to a study conducted by researchers at Korea University Guro Hospital and Korea University College of Medicine. For patients over 70, the drug offered no survival advantage and led to higher rates of treatment discontinuation due to toxicity.
